GILDKite, A Gilead CompanyRunning, no new patients
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Follicular Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 231 (final count)
- Started
- Sep 22, 2022
- Main results expected
- Oct 2030
- Fully finished
- Oct 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) as Assessed by Blinded Central Assessment per Lugano Classification
Measured over: Up to 5 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05371093 · record last updated 2025-10-15 · checked 2026-11-09 15:47 UTC